Lam Research Stock Rockets 21% With 5-Day Winning Streak
Lam Research (LRCX) – a semiconductor equipment designer and service provider – hit a 5-day winning streak, with cumulative gains over this period amounting to 21%. The company’s market cap has surged by about $57 Bil over the last 5 days and currently stands at $331 Bil.
Is this an opportunity or a trap? There is not much to fear in LRCX stock given its overall Very Strong operating performance and financial condition. Hence, despite its Very High valuation, the stock appears Attractive but Volatile (For details, see Buy or Sell LRCX).
But here is the interesting part. You are reading about this 21% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. High Quality Portfolio is based on an architecture that includes such signals.
Returns vs S&P 500
- Has HCA Healthcare Stock Quietly Become a Value Opportunity?
- This Strategy Pays You 13% While Lining Up RCL at Bargain Prices
- Cash Machine Trading Cheap – Gartner Stock Set to Run?
- Years of Rewards: $32 Bil From United Parcel Service Stock
- Five-Year Tally: Booking Stock Delivers $33 Bil Gain
- Super Micro Computer Stock at Support Zone – Bargain or Trap?
The following table summarizes the return for LRCX stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | LRCX | S&P 500 |
|---|---|---|
| 1D | 1.9% | -0.1% |
| 5D (Current Streak) | 20.7% | 3.6% |
| 1M (21D) | 20.5% | 0.6% |
| 3M (63D) | 31.4% | -1.5% |
| YTD 2026 | 54.2% | -0.4% |
| 2025 | 139.2% | 16.4% |
| 2024 | -6.8% | 23.3% |
| 2023 | 88.6% | 24.2% |
However, big gains can follow sharp reversals – but how has LRCX behaved after prior drops? See LRCX Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 85 S&P constituents with 3 days or more of consecutive gains and 44 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 30 | 18 |
| 4D | 24 | 11 |
| 5D | 18 | 12 |
| 6D | 2 | 0 |
| 7D or more | 11 | 3 |
| Total >=3 D | 85 | 44 |
Key Financials for Lam Research (LRCX)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $14.9 Bil | $18.4 Bil |
| Operating Income | $4.3 Bil | $5.9 Bil |
| Net Income | $3.8 Bil | $5.4 Bil |
Last 2 Fiscal Quarters:
| Metric | 2026 FQ1 | 2026 FQ2 |
|---|---|---|
| Revenues | $5.3 Bil | $5.3 Bil |
| Operating Income | $1.8 Bil | $1.8 Bil |
| Net Income | $1.6 Bil | $1.6 Bil |
While LRCX stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.